{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,9,30]],"date-time":"2026-09-30T05:22:38Z","timestamp":1790745758776,"version":"4.1.0"},"reference-count":28,"publisher":"Ovid Technologies (Wolters Kluwer Health)","issue":"5","license":[{"start":{"date-parts":[[2022,5,1]],"date-time":"2022-05-01T00:00:00Z","timestamp":1651363200000},"content-version":"unspecified","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by-nc-nd\/4.0\/"}],"content-domain":{"domain":["lww.com","ovid.com"],"crossmark-restriction":true},"short-container-title":[],"abstract":"<jats:sec>\n            <jats:title>IMPORTANCE:<\/jats:title>\n            <jats:p>Despite high mortality rates of COVID-19-associated pulmonary aspergillosis (CAPA) in the ICU, antifungal prophylaxis remains a subject of debate. We initiated nebulized conventional amphotericin B (c-AmB) as antifungal prophylaxis in COVID-19 patients on invasive mechanical ventilation (IMV).<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>OBJECTIVES:<\/jats:title>\n            <jats:p>To assess the CAPA incidence in COVID-19 patients on IMV treated with and without nebulized c-AmB as antifungal prophylaxis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>DESIGN, SETTING, AND PARTICIPANTS:<\/jats:title>\n            <jats:p>Retrospective cohort study of consecutive COVID-19 patients admitted to our adult 17-bed ICU in a university-affiliated general hospital in Ede, The Netherlands, between January 25, 2021, and July 9, 2021. Patients not requiring IMV or transferred from or to another ICU were excluded. From April 9, 2021, daily nebulized amphotericin B in all patients on IMV was initiated.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>MAIN OUTCOMES AND MEASURES:<\/jats:title>\n            <jats:p>Bronchoscopy with bronchoalveolar lavage (BAL) was performed in case of positive cultures for <jats:italic toggle=\"yes\">Aspergillus<\/jats:italic> from the respiratory tract and\/or unexplained respiratory deterioration. Incidence of probable and proven CAPA was compared between patients treated with and without nebulized antifungal prophylaxis using Pearson chi-square test.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>RESULTS:<\/jats:title>\n            <jats:p>A total of 39 intubated COVID-19 patients could be analyzed, of which 16 were treated with antifungal prophylaxis and 23 were not. Twenty-six patients underwent bronchoscopy with BAL. In patients treated with antifungal prophylaxis, the incidence of probable\/proven CAPA was significantly lower when compared with no antifungal prophylaxis (27% vs 67%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.047). Incidence of tracheobronchial lesions and positive <jats:italic toggle=\"yes\">Aspergillus<\/jats:italic> cultures and BAL-galactomannan was significantly lower in patients treated with antifungal prophylaxis (9% vs 47%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.040, 9% vs 53%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.044, and 20% vs 60%; <jats:italic toggle=\"yes\">p<\/jats:italic> = 0.047, respectively). No treatment-related adverse events and no case of proven CAPA were encountered in patients receiving antifungal prophylaxis.<\/jats:p>\n          <\/jats:sec>\n          <jats:sec>\n            <jats:title>CONCLUSIONS AND RELEVANCE:<\/jats:title>\n            <jats:p>Nebulization of c-AmB in critically ill COVID-19 patients on IMV is safe and may be considered as antifungal prophylaxis to prevent CAPA. However, a randomized controlled trial to confirm this is warranted.<\/jats:p>\n          <\/jats:sec>","DOI":"10.1097\/cce.0000000000000696","type":"journal-article","created":{"date-parts":[[2022,5,9]],"date-time":"2022-05-09T22:00:07Z","timestamp":1652133607000},"page":"e0696","update-policy":"https:\/\/doi.org\/10.1097\/lww.0000000000001000","source":"Crossref","is-referenced-by-count":18,"title":["Nebulized Amphotericin B in Mechanically Ventilated COVID-19 Patients to Prevent Invasive Pulmonary Aspergillosis: A Retrospective Cohort Study"],"prefix":"10.1097","volume":"4","author":[{"given":"Max","family":"Melchers","sequence":"first","affiliation":[{"name":"Department of Intensive Care Medicine, Gelderse Vallei Hospital, Ede, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Arthur R. H.","family":"van Zanten","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Gelderse Vallei Hospital, Ede, The Netherlands."},{"name":"Division of Human Nutrition and Health, Wageningen University & Research, Wageningen, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Moniek","family":"Heusinkveld","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, Gelderse Vallei Hospital, Ede, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Jan Willem","family":"Leeuwis","sequence":"additional","affiliation":[{"name":"Department of Pathology, Rijnstate Hospital, Arnhem, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Roel","family":"Schellaars","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Gelderse Vallei Hospital, Ede, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hendrick J. W.","family":"Lammers","sequence":"additional","affiliation":[{"name":"Department of Pharmacy, Gelderse Vallei Hospital, Ede, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Freek J.","family":"Kreemer","sequence":"additional","affiliation":[{"name":"Department of Pulmonary Medicine, Gelderse Vallei Hospital, Ede, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Pieter-Jan","family":"Haas","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology, University Medical Center Utrecht, Utrecht, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Paul E.","family":"Verweij","sequence":"additional","affiliation":[{"name":"Department of Medical Microbiology and Radboudumc-CWZ Center of Expertise for Mycology, Radboud University Medical Center, Nijmegen, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Sjoerd H. W.","family":"van Bree","sequence":"additional","affiliation":[{"name":"Department of Intensive Care Medicine, Gelderse Vallei Hospital, Ede, The Netherlands."}],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"276","published-online":{"date-parts":[[2022,5,9]]},"reference":[{"key":"R1-20240807","doi-asserted-by":"crossref","first-page":"e149","DOI":"10.1016\/S1473-3099(20)30847-1","article-title":"Defining and managing COVID-19-associated pulmonary aspergillosis: The 2020 ECMM\/ISHAM consensus criteria for research and clinical guidance.","volume":"21","author":"Koehler","year":"2021","journal-title":"Lancet Infect Dis"},{"key":"R2-20240807","doi-asserted-by":"crossref","first-page":"132","DOI":"10.1164\/rccm.202004-1038LE","article-title":"COVID-19-associated pulmonary aspergillosis.","volume":"202","author":"van Arkel","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R3-20240807","doi-asserted-by":"crossref","first-page":"180","DOI":"10.1016\/S2213-2600(21)00442-2","article-title":"Fungal infections in mechanically ventilated patients with COVID-19 during the first wave: The French multicentre MYCOVID study.","volume":"10","author":"Gangneux","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R4-20240807","doi-asserted-by":"crossref","first-page":"753659","DOI":"10.3389\/fmed.2021.753659","article-title":"Risk factors for invasive aspergillosis in patients admitted to the intensive care unit with coronavirus disease 2019: A multicenter retrospective study.","volume":"8","author":"Xu","year":"2021","journal-title":"Front Med (Lausanne)"},{"key":"R5-20240807","doi-asserted-by":"crossref","first-page":"1067","DOI":"10.3390\/jof7121067","article-title":"A visual and comprehensive review on COVID-19-associated pulmonary aspergillosis (CAPA).","volume":"7","author":"Feys","year":"2021","journal-title":"J Fungi (Basel)"},{"key":"R6-20240807","doi-asserted-by":"crossref","first-page":"127","DOI":"10.1016\/S2213-2600(21)00500-2","article-title":"Managing secondary fungal infections in severe COVID-19: How to move forward?","volume":"10","author":"Verweij","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R7-20240807","doi-asserted-by":"crossref","first-page":"674","DOI":"10.1007\/s00134-021-06431-0","article-title":"Posaconazole for prevention of invasive pulmonary aspergillosis in critically ill influenza patients (POSA-FLU): A randomised, open-label, proof-of-concept trial.","volume":"47","author":"Vanderbeke","year":"2021","journal-title":"Intensive Care Med"},{"key":"R8-20240807","doi-asserted-by":"crossref","first-page":"335","DOI":"10.1186\/s13054-021-03753-9","article-title":"Antifungal prophylaxis for prevention of COVID-19-associated pulmonary aspergillosis in critically ill patients: An observational study.","volume":"25","author":"Hatzl","year":"2021","journal-title":"Crit Care"},{"key":"R9-20240807","doi-asserted-by":"crossref","first-page":"298","DOI":"10.1186\/s13054-021-03728-w","article-title":"Inhaled liposomal amphotericin-B as a prophylactic treatment for COVID-19-associated pulmonary aspergillosis\/aspergillus tracheobronchitis.","volume":"25","author":"Van Ackerbroeck","year":"2021","journal-title":"Crit Care"},{"key":"R10-20240807","doi-asserted-by":"crossref","first-page":"1401","DOI":"10.1086\/586739","article-title":"Aerosolized liposomal amphotericin B for the prevention of invasive pulmonary aspergillosis during prolonged neutropenia: A randomized, placebo-controlled trial.","volume":"46","author":"Rijnders","year":"2008","journal-title":"Clin Infect Dis"},{"key":"R11-20240807","doi-asserted-by":"crossref","DOI":"10.1177\/1178636119869937","article-title":"Inhaled amphotericin B as aspergillosis prophylaxis in hematologic disease: An update.","volume":"12","author":"Duckwall","year":"2019","journal-title":"Microbiol Insights"},{"key":"R12-20240807","doi-asserted-by":"crossref","first-page":"82","DOI":"10.1016\/j.ijantimicag.2015.02.023","article-title":"Aerosolised liposomal amphotericin B to prevent aspergillosis in acute myeloid leukaemia: Efficacy and cost effectiveness in real-life.","volume":"46","author":"Chong","year":"2015","journal-title":"Int J Antimicrob Agents"},{"key":"R13-20240807","doi-asserted-by":"crossref","first-page":"30","DOI":"10.1016\/j.drup.2015.08.001","article-title":"International expert opinion on the management of infection caused by azole-resistant Aspergillus fumigatus.","volume":"21\u201322","author":"Verweij","year":"2015","journal-title":"Drug Resist Updat"},{"key":"R14-20240807","doi-asserted-by":"crossref","first-page":"708","DOI":"10.1164\/rccm.201910-1931OC","article-title":"Invasive tracheobronchial aspergillosis in critically ill patients with severe influenza. A clinical trial.","volume":"202","author":"Nyga","year":"2020","journal-title":"Am J Respir Crit Care Med"},{"key":"R15-20240807","doi-asserted-by":"crossref","first-page":"795","DOI":"10.1016\/S2213-2600(21)00138-7","article-title":"COVID-19-associated Aspergillus tracheobronchitis: The interplay between viral tropism, host defence, and fungal invasion.","volume":"9","author":"van de Veerdonk","year":"2021","journal-title":"Lancet Respir Med"},{"key":"R16-20240807","doi-asserted-by":"crossref","first-page":"2798","DOI":"10.1128\/JCM.01185-16","article-title":"Discrimination of aspergillosis, mucormycosis, fusariosis, and scedosporiosis in formalin-fixed paraffin-embedded tissue specimens by use of multiple real-time quantitative PCR assays.","volume":"54","author":"Salehi","year":"2016","journal-title":"J Clin Microbiol"},{"key":"R17-20240807","doi-asserted-by":"crossref","first-page":"1478","DOI":"10.1128\/JCM.02221-09","article-title":"Rapid diagnosis of azole-resistant aspergillosis by direct PCR using tissue specimens.","volume":"48","author":"van der Linden","year":"2010","journal-title":"J Clin Microbiol"},{"key":"R18-20240807","doi-asserted-by":"crossref","first-page":"2892","DOI":"10.3201\/eid2711.211174","article-title":"Multinational observational cohort study of COVID-19-associated pulmonary aspergillosis1.","volume":"27","author":"Janssen","year":"2021","journal-title":"Emerg Infect Dis"},{"key":"R19-20240807","doi-asserted-by":"crossref","first-page":"580","DOI":"10.1016\/j.cmi.2021.08.014","article-title":"Risk factors and outcome of pulmonary aspergillosis in critically ill coronavirus disease 2019 patients-a multinational observational study by the European Confederation of Medical Mycology.","volume":"28","author":"Prattes","year":"2021","journal-title":"Clin Microbiol Infect"},{"key":"R20-20240807","doi-asserted-by":"crossref","first-page":"e0122921","DOI":"10.1128\/JCM.01229-21","article-title":"Aspergillus test profiles and mortality in critically ill COVID-19 patients.","volume":"59","author":"Erg\u00fcn","year":"2021","journal-title":"J Clin Microbiol"},{"key":"R21-20240807","doi-asserted-by":"crossref","first-page":"1491","DOI":"10.1056\/NEJMoa2100433","article-title":"Interleukin-6 receptor antagonists in critically ill patients with Covid-19.","volume":"384","author":"Gordon","year":"2021","journal-title":"N Engl J Med"},{"key":"R22-20240807","doi-asserted-by":"crossref","first-page":"1637","DOI":"10.1016\/S0140-6736(21)00676-0","article-title":"Tocilizumab in patients admitted to hospital with COVID-19 (RECOVERY): A randomised, controlled, open-label, platform trial.","volume":"397","year":"2021","journal-title":"Lancet"},{"key":"R23-20240807","doi-asserted-by":"crossref","first-page":"e1","DOI":"10.1093\/cid\/ciw326","article-title":"Practice guidelines for the diagnosis and management of aspergillosis: 2016 update by the Infectious Diseases Society of America.","volume":"63","author":"Patterson","year":"2016","journal-title":"Clin Infect Dis"},{"key":"R24-20240807","doi-asserted-by":"crossref","first-page":"e005116","DOI":"10.1099\/jmmcr.0.005116","article-title":"False-positive galactomannan assay in broncho-alveolar lavage after enteral nutrition solution inhalation: A case report.","volume":"4","author":"Lheureux","year":"2017","journal-title":"JMM Case Rep"},{"key":"R25-20240807","doi-asserted-by":"crossref","first-page":"JCM0216921","DOI":"10.1128\/jcm.02169-21","article-title":"Combination of mycological criteria: A better surrogate to identify COVID-19 associated pulmonary aspergillosis patients and evaluate prognosis?","volume":"60","author":"Delli\u00e8re","year":"2022","journal-title":"J Clin Microbiol"},{"key":"R26-20240807","doi-asserted-by":"crossref","first-page":"360","DOI":"10.1007\/s00134-021-06603-y","article-title":"Inhaled amphotericin B lipid complex for prophylaxis against COVID-19-associated invasive pulmonary aspergillosis.","volume":"48","author":"Soriano","year":"2021","journal-title":"Intensive Care Med"},{"key":"R27-20240807","doi-asserted-by":"crossref","first-page":"931","DOI":"10.1586\/14787210.2013.826989","article-title":"Therapeutic drug monitoring of voriconazole and posaconazole for invasive aspergillosis.","volume":"11","author":"Seyedmousavi","year":"2013","journal-title":"Expert Rev Anti Infect Ther"},{"key":"R28-20240807","doi-asserted-by":"crossref","first-page":"1703","DOI":"10.1007\/s40265-021-01611-0","article-title":"The antifungal pipeline: Fosmanogepix, ibrexafungerp, olorofim, opelconazole, and rezafungin.","volume":"81","author":"Hoenigl","year":"2021","journal-title":"Drugs"}],"container-title":["Critical Care Explorations"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000696","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,8,7]],"date-time":"2024-08-07T14:17:53Z","timestamp":1723040273000},"score":1,"resource":{"primary":{"URL":"https:\/\/journals.lww.com\/10.1097\/CCE.0000000000000696"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2022,5]]},"references-count":28,"journal-issue":{"issue":"5","published-online":{"date-parts":[[2022]]}},"URL":"https:\/\/doi.org\/10.1097\/cce.0000000000000696","relation":{},"ISSN":["2639-8028"],"issn-type":[{"value":"2639-8028","type":"electronic"}],"subject":[],"published":{"date-parts":[[2022,5]]}}}